Your Knee Called. It Wants New Cartilage.
Renovare Therapeutics launches from stealth with up to $33.5M in ARPA-H funding for osteoarthritis regeneration.
Category Emerging Modalities
No Drugs. Just Ultrasound.
SonoNeu exits stealth with $5.2M from a $41.3M ARPA-H program to bring sonogenetics to the clinic.
Neutrolis Posts Positive Phase 1a Data for First-in-Class NET-Targeting Therapy
NTR-1011 is the first drug designed to dismantle neutrophil extracellular traps — and early safety data just cleared the way for lupus and RA patients.
Alltrna Sends the First tRNA Therapeutic Into Human Testing
Alltrna's AP003 just became the first tRNA-based drug to enter clinical trials — a milestone for an entirely new modality.
Stop Inhibiting. Start Destroying.
TRIANA Biomedicines doses the first patient with TRI-611, a brain-penetrant molecular glue degrader that eliminates ALK fusion proteins — not just blocks them.
What If B-Cell Depletion Didn’t Need T Cells at All?
Commit Biologics raises €21.5M to weaponize the complement system against B cells — no cytokine storm required.
The Splice Between Gene Editing and Gene Therapy
Tacit Therapeutics launches with $19M to build RNA splicing therapies that fix mutations without touching DNA.
CRISPR Just Became an Antibiotic. Sort Of.
SNIPR Biome publishes first clinical proof that CRISPR-engineered phages can selectively kill bacteria in the human gut.